Evidence mapPaperPMID 38908832Full record

ReviewJournal of thrombosis and haemostasis : JTH2024

Venous thromboembolic disease genetics: from variants to function.

Mary Underwood, Christopher Bidlack, Karl C Desch

Abstract readReview
In one paragraph

Review in Journal of thrombosis and haemostasis : JTH, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mary UnderwoodDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Christopher BidlackCellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan, USA.
Karl C DeschDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA; Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: kdesch@med.umich.edu.

Funding

The Molecular Genetics of Von Willebrand Factor SecretionR01HL172780 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$583k
NHLBI NIH HHS R01 HL141399NHLBI NIH HHS R01 HL172780
6 · The paper itself

Abstract

Venous thromboembolic disease (VTE) is a prevalent and potentially life-threatening vascular disease, including both deep vein thrombosis and pulmonary embolism. This review will focus on recent insights into the heritable factors that influence an individual's risk for VTE. Here, we will explore not only the discovery of new genetic risk variants but also the importance of functional characterization of these variants. These genome-wide studies should lead to a better understanding of the biological role of genes inside and outside of the canonical coagulation system in thrombus formation and lead to an improved ability to predict an individual's risk of VTE. Further understanding of the molecular mechanisms altered by genetic variation in VTE risk will be accelerated by further human genome sequencing efforts and the use of functional genetic screens.

Indexed as

Genetic Predisposition to DiseaseGenetic VariationVenous ThromboembolismBlood CoagulationGenome-Wide Association StudyHumansPhenotypePulmonary EmbolismRisk FactorsVenous ThrombosisanticoagulantsCRISPRgenome-wide association studysecretory pathwayvenous thrombosis

Identifiers

PMID38908832
PMCPMC11934295

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.